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The peroxisome proliferator-activated receptors (PPARs) are
membersofthenuclearreceptorsuperfamily thatactastran-
scriptionfactorsandplayimportantrolesintheregulationof
a variety of biological processes, such as adipocyte prolifer-
ation and diﬀerentiation, glucose homeostasis, intracellular
traﬃcking of lipids and their metabolism, inﬂammatory
responses,vascularfunctions,andembryonicandfetaldevel-
opment. Three PPAR subtypes have been identiﬁed: PPARα,
PPARβ/δ,a n dP P A R γ (with isoforms PPARγ1a n dP P A R γ2),
each with overlapping but unique ligand speciﬁcity, patterns
of tissue distribution, and biological functions. The mecha-
nismsofPPARactionhavebeenwell studied[1].Thenuclear
receptors are activated by their ligands, heterodimerize
with another nuclear receptor, retinoid X receptor (RXR),
and undergo speciﬁc conformational changes that release
corepressors and allow for recruitment of coactivators. The
receptor complex binds to speciﬁc DNA sequences, called
peroxisome proliferator response elements (PPREs), in the
promoter regions of target genes for transactivation as well
as transrepression. Activated genes are associated with fatty
acid transport and metabolism, adipogenesis, peroxisome
biogenesis, cholesterol and bile acid biosynthesis, protea-
some activation, and glucose metabolism; repressed genes
typically include those involved with adaptive inﬂammatory
responses.
Anumberofendogenousligandshavebeenidentiﬁedfor
each PPAR subtype and include long-chain polyunsaturated
fatty acids such as linoleic and arachidonic acids, saturated
fatty acids, and eicosanoids. Because of the involvement of
PPARs in controlling energy homeostasis, synthetic chemi-
cals have been designed to interact with these nuclear recep-
tors for therapeutic intervention of a number of metabolic
diseases such as obesity, type-2 diabetes, and atherosclerosis.
Indeed, in the past several decades, speciﬁc pharmacologic
agents such as the ﬁbrates (that include cloﬁbrate, fenoﬁ-
brate, ciproﬁbrate, bezaﬁbrate, and gemﬁbrozil) and the
glitazones (such as ciglitazone, troglitazone, rosiglitazone
and pioglitazone) have been developed that target PPARα
and PPARγ, respectively, for the eﬀectivetreatment ofhyper-
lipidemia and diabetes. Since 1990 when the PPAR family
members were clonedand characterized, a number of indus-
trial and consumer chemicals, pesticides, and environmental
contaminants have been shown to activate PPARs. These
include di-(2-ethylhexyl)phthalate (DEPH) [2], diisobutyl
phthalate[3],trichloroethylene,di-andtrichloroaceticacids,
[4], bisphenol A [5], butylparaben [3], perﬂuoroalkyl acids
(PFAAs) [6], and organotins [7]. Systematic screening of
chemicals in commerce and in the environment for PPAR
molecular signature and functional activities may further
expand the existing list [8–10]. However, the potential
human and ecological health risks from such chemically
induced PPAR activation are still relatively unknown and
presently subject to great debate.
This special issue is organized to highlight the recent
advances made in identifying drugs and chemicals that tar-
get PPARs as their mechanism-of-action, in characterizing2 PPAR Research
the downstream biochemical and physiological consequen-
ces from these drug actions and chemical insults, and in
addressing the relevance of this mechanism-of-action and
toxicity for human health risks. This issue will focus on both
cancer and noncancer eﬀects (that include reproductive,
developmental,immunologicandmetabolicendpoints),and
unique actions mediated by the diﬀerent PPAR subtypes.
There are eight papers in this special issue, including
ﬁve original research articles and three reviews. In the ﬁrst
research article, “Peroxisome proliferator-activated receptors
alpha, beta, and gamma mRNA and protein expression human
fetal tissues,” B. D. Abbott et al. characterize the mRNA and
protein expression of the three PPAR subtypes in human
fetal tissues. With the exception of one study that previously
described the expression of PPAR proteins in the human
fetal digestive tract, this is the ﬁrst comprehensive report to
compare the expression of these nuclear receptor subtypes
in human fetal liver, heart, lung, kidney, stomach, intestine,
adrenal, spleen and thymus during organogenesis, and to
contrast the levels of expression in the fetus to those in
adult tissues. This study reports that PPARα, β and γ were
expressed in all nine human fetal tissues evaluated. In gen-
eral, mRNA expression of PPAR subtypes varied by tissue;
notably,the levelsin fetus were comparable to orevenhigher
than those in adult, a pattern similar to that observed in
rodents. These ﬁndings indicate that PPARs likely serve key
roles in regulating developmental events, and inappropriate
or untimely activation of these nuclear receptors (through
transplacental delivery of drugs or exposure to xenobiotic
chemicals) may bear untoward health consequences. Sub-
sequent to the appearance of this paper online, these in-
vestigators discovered an artifact in their detection for
PPARγ proteins, and have conducted an additional study to
rectify the unexpected error. The replacement ﬁndings have
now been published in “Erratum to “Peroxisome proliferator
activatedreceptors alpha, beta,and gammamRNA and protein
expression in human fetal tissues,”” and the new protein
results are in good agreement with the patterns of expression
obtained for PPARγ mRNA in these tissues.
In a review article entitled “The role of PPARα activation
in liver and muscle,” L. Burri et al. summarize the involve-
ment of PPARα in two metabolically active tissues, liver
and skeletal muscle, and provide a comparative overview
of the beneﬁts and risks of PPARα activation in humans
and rodents. The beneﬁcial eﬀects of PPARα activation in
counteractingmetabolicdisordersare well supportedinboth
animal and human studies. Indeed, both species share mul-
tiple changes in expression of genes that belong to functional
classes related to lipid metabolism. Yet, there are substantial
diﬀerences between human and mouse target gene expres-
sion in response to PPARα activation in the liver, particularly
those associated with peroxisome proliferation, hypertrophy,
hyperplasia, apoptosis and tumor induction. The responses
to PPARα activation appear to be more pronounced in
mice than in humans. In contrast to mice, humans show
no eﬀect on glucose metabolism in response to PPARα ac-
tivation; conversely, apolipoprotein production that leads to
a decrease of VLDL and an increase of HDL cholesterol
is only seen in humans treated with a PPARα activator.
PPARs are expressed in skeletal muscles in humans and rats;
activation ofthese nuclear receptorsincreases lipid oxidation
and decreases triglyceride accumulation and alters glucose
metabolism. These investigators note a sex diﬀerence in
both humans and rodents in response to PPARα activation
and caution that gender diﬀerences should be taken into
consideration for therapy involving PPARs.
The theme of sex diﬀerences related to PPARα eﬀects is
continued in a second review article presented by M. Yoon
“PPARα in obesity: sex diﬀerence and estrogen involvement”
who describessexual dimorphism inthetreatment ofobesity
by PPARα ligands and summarizes the involvement of estro-
gen. Both PPARα and estrogen receptors (ERs) are involved
in regulating adiposity. Interestingly, PPAR/RXR heterodim-
ers have been shown to bind to estrogen response elements,
and PPARs and ERs share certain cofactors, suggesting that
signal cross-talk between these two nuclear receptors may
participate in the control of obesity. However, sex-related
differences have been reported in PPARα eﬀects in animal
studies. Fenoﬁbrate reduced weight gain and adiposity in
male mice given a high-fat diet and reduced circulating
cholesterol and triglycerides, while females exhibit drug re-
sistance. In fact, estrogens appear to inhibit PPARαaction on
obesity. While both fenoﬁbrate and estradiol (E2) by them-
selves were eﬀective in attenuating weight gain and increases
of fat mass in mice fed a high-fat diet, combined fenoﬁbrate
and E2 treatment did not produce any additional eﬀects;
the combined treatment actually led to elevated levels of
circulating cholesterol and triglycerides compared to those
with each treatment alone. Findings from animal studies are
by and large in agreement with clinical observations. Details
about the interplay between PPARα and ERs are presently
unavailable, but competition between these two nuclear re-
ceptorsfortranscriptional coactivatorsand corepressors may
confer a negative cross-talk between their actions.
A research article by M. Cunningham et al. “Eﬀects of the
PPARα agonist and widely used antihyperlipidemic drug gem-
ﬁbrozil on hepatic toxicity and lipid metabolism” follows the
discussion of the use of antihyperlipidemic drugs, focusing
on lipid metabolism and hepatic toxicity of another ﬁbrate,
gemﬁbrozil, and comparing the responses between rats,
mice, and hamsters. Gemﬁbrozil is a valuable therapeutic
agent in the control of coronary heart disease, in part due
to its hypolipidemic eﬀects in reducing levels of triglycerides
and LDL cholesterol and raising those of HDL. Similar to
other peroxisome proliferators, gemﬁbrozil is known to in-
duce liver hypertrophy and tumors in rodents. This paper
summarizes the results of several studies conducted by the
NationalToxicologyProgramtoevaluatetheeﬀectsofchron-
ic exposure to gemﬁbrozil in rats and mice; evaluation of
hamsters is included because this species, like humans, is rel-
atively resistant to the hepatotoxicity and carcinogenicity of
peroxisome proliferators. In general, hepatic eﬀects of gem-
ﬁbrozil were seen in all three species, although rats appeared
to be most responsive and hamsters to be least responsive.
Correspondingly, a similar rank order of species diﬀerence
was noted in the oxidative stress-related mechanisms-of-
action produced by gemﬁbrozil, which may be related to
the diﬀerential susceptibility to the hepatocarcinogenicity ofPPAR Research 3
this drug. Information provided in this paper should lend
support in diﬀerentiating the beneﬁcial eﬀects of PPARα
drugs in treating dyslipidemia and their potential risks of
tumor induction.
Two research articles by C. J. Wolf et al., “Developmental
eﬀects of perﬂuorononanoic acid in the mouse are dependent
on peroxisome proliferator-activated receptor-alpha,” and M.
B. Rosen et al., “Gene expression proﬁling in wild-type and
PPARα-null mice exposed to perﬂuorooctane sulfonate reveals
PPARα-independent eﬀects,” address the potential human
health risks of perﬂuoroalkyl acids, a class of persistent en-
vironmental contaminants that has received intense scrutiny
from regulatory agencies worldwide. PFAAs are found ubiq-
uitously in all environmental media, distributed globally,
present in humans and wildlife, and associated with several
adverse eﬀects in laboratory animal models. These chemicals
vary in carbon-chain lengths and functional groups (chieﬂy
carboxylatesand sulfonates),butall appeartoactivatemouse
and human PPARα[6]. PPARαactivationby PFAAshasbeen
shown previously to be related to their hepatotoxicity, devel-
opmental toxicity, and immunotoxicity in rodents. Results
from previous studies with transgenic PPARα-null mice
have indicated that developmental toxicity of perﬂuorooc-
tanoate (PFOA), but not that of perﬂuororooctane sulfonate
(PFOS), is dependent on PPARα [11, 12]. Using a similar
experimental design, C. J. Wolf et al. in “Developmental
eﬀects of perﬂuorononanoic acid in the mouse are dependent
on peroxisome proliferator-activated receptor-alpha”r e p o r t
that the adverse developmental eﬀects of perﬂuorononanoic
acid (PFNA) were more pronounced than those of PFOA,
but also dependent on a PPARα mechanism. Thus, neo-
natal mortality (at high doses), growth impairment and
developmental delays (at lower doses) were observed in
wild-type mice but not in PPARα-null mice after gestational
exposure toPFNA.These resultstherefore conﬁrmadiﬀerent
mode-of-action for developmental eﬀects between the
perﬂuoroalkyl carboxylates and perﬂuoroalkyl sulfonates,
and that the chemical potency of PFAAs increases with
carbon-chain length. In contrast, the phenotypic responses
in the liver of mice exposed to PFOA or PFOS are quite
similar. Both ﬂuorochemicals activate PPARα and its target
genes, inducing peroxisome proliferation, hypertrophy and
t u m o r si nt h el i v e r .H o w e v e r ,M .B .R o s e na n dc o w o r k e r s
in “Gene expression proﬁling in wild-type and PPARα-null
mice exposed to perﬂuorooctane sulfonate reveals PPARα-in-
dependent eﬀects” report a number of genomic changes
associated with lipid metabolism, inﬂammation and xeno-
bioticmetabolism thatare independentofPPARαactivation;
rather, these gene expressions may be related to PPARγ,
PPARβ, or another nuclear receptor, the constitutive andro-
stane receptor (CAR), thus indicating the possibility of
multiple modes-of-action for PFAA hepatic eﬀects. In addi-
tion, altered expression of certain genes unique to PFOS
exposure was identiﬁed, including those associated with ri-
bosome biogenesis, oxidative phosphorylation and choles-
terol biosynthesis. These ﬁndings should provide valuable
supportfortheassessment ofhumanhealth risksofexposure
to these environmental contaminants.
Continuing the exploration of target genes activated
by PPARα and their attendant functional responses, H.
Ren et al. in “Regulation of proteome maintenance gene
expression by activators of peroxisome proliferator-activated
receptorα” focus on the regulation of proteome maintenance
(PM) by this nuclear receptor. Increased oxidative stress
caused by chemical or physical insult can lead to misfolding
or other damage to protein, and restoration of cellular
homeostasis entails stabilization of unfolded proteins by
molecular chaperones (such as heat shock proteins, Hsp)
or removal of damaged proteins by proteolysis. Ample
evidence has suggested that PPARα protects multiple tissues
from oxidative stress induced by chemicals through altered
expression of genes involved in proteome maintenance,
including those in the Hsp family and proteasomal genes
involved in proteolysis. These investigators compare and
contrast the expression of PM genes with traditional target
genes (e.g., lipid metabolizing enzymes) in rodent liver after
exposure to seven diverse peroxisome proliferators (WY
14,643,ﬁbrates,valproicacid,DEHP,andPFAAs).Genesand
proteins involved in proteome maintenance were altered by
these peroxisome proliferators, although the expression of
many of these genes appeared to be delayed or transient, and
was distinctly diﬀerentfrom othertypical PPARα-dependent
genes. These results therefore support an expanded role
for PPARα in regulating genes and proteins that serve as
guardians of the proteome, in addition to controlling lipid
metabolism and energy balance.
A. Rogue et al. in “Gene expression changes induced by
PPAR gamma agonists in animal and human liver,” sum-
marize the changes of hepatic gene expression induced by
PPARγ agonists in animal models and humans. PPARγ is
highly expressed in adipose tissues, and to a much lesser
extent in the liver. PPARγ drugs such as the glitazones are
used to treat type-2 diabetes. They enhance insulin sen-
sitivity presumably by channeling circulating fatty acids
into adipose tissue. However, side eﬀects of at least one of
these agents include idiosyncratic hepatotoxicity, although
the determinant factors for the untoward actions of PPARγ
agonists remain to be elucidated. The authors compare the
gene expression proﬁles of PPARγ activation derived from
in vivo studies with rodent livers to those obtained from
in vitro studies with rat and human hepatocytes. PPARγ
levels are enhanced in obese and diabetic mouse liver,
and the steatogenic responses to glitazone in these rodent
m o d e l sa r em o r ep r o n o u n c e dt h a nt h o s es e e ni nt h el e a n
controls. The genomic responses to PPARγ agonists in the
liver mirror the tissue distribution proﬁle of this nuclear
receptor; hence, only a small number of genes were aﬀected
in the liver compared to the adipose tissues. Only limited
studies are available with human liver cells, and results
from individual donors are quite variable, perhaps in line
with the idiosyncratic nature of the hepatotoxicity observed.
Future studies identifying speciﬁc PPARγ genes in the liver
will elucidate the etiology of hepatotoxicity associated with
PPARγ agonists, particularly after long-term therapeutic
treatment.
In summary, this special issue provides a glimpse of the
current understanding of PPAR involvement in therapeutic4 PPAR Research
interventions, as well as the untoward side eﬀects, and the
potential health risks from exposure to xenobiotic chemicals
foundintheenvironment.Thesereviewsandresearch papers
contribute signiﬁcantly to our understanding of these in-
triguing nuclear receptor signaling molecules.
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